Speaker’s Title: Xiaodong Liu, Ph.D., Chief Scientist, NanoChrom Technologies
Bio-therapeutics have gained significant momentum due to their specificity and effectiveness in diagnosing and treating diverse diseases. In the development and manufacturing of these bio-therapeutics, it is crucial to monitor, characterize, and quantify impurities, structural variants, and post-translational modifications to ensure the safety and efficacy of the final products.
High-Performance Liquid Chromatography (HPLC) plays a pivotal role in the analytical process for characterizing and quantifying impurities and variants in antibody-based bio-therapeutics. Given the complex nature of these substances, a range of columns utilizing different separation modes, such as Size Exclusion Chromatography (SEC), Ion Exchange Chromatography (IEC), Hydrophobic Interaction Chromatography (HIC), Reversed-Phase Chromatography (RPC), Hydrophilic Interaction Chromatography (HILIC), and Protein A affinity chromatography, are employed to achieve comprehensive characterization.
Join our upcoming webinar where we will provide a comprehensive overview of Liquid Chromatography (LC) columns, delving into separation mechanisms and column technologies. The focus will be on aggregates and charged variants in antibody-based biologics. We will address common challenges related to resolution, throughput, reproducibility, durability, and scalability in the context of bio-therapeutics development and production.
Key Learning Objectives:
- Acquire knowledge on column technology used in the separation of antibody-based biologics.
- Explore solutions to typical challenges encountered in chromatographic analysis of antibody-based biologics.
- Delve into applications spanning monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), fusion proteins, and more.
Who Should Attend:
- Researchers responsible for the development and/or management of Liquid Chromatography (LC) methods in bio-pharmaceutical laboratories.
- Laboratory managers guiding teams dedicated to the analysis of antibody-based biologics and associated substances.
Dr. Xiaodong Liu received his Ph.D. in Chemistry from Iowa State University. He initiated his career as a research scientist in the Research and Development department at Dionex Corporation, which was later acquired by Thermo Fisher Scientific. Over time, he progressed to the role of R&D director, overseeing all research and development activities related to chromatography consumables within the company. In 2018, Dr. Liu founded NanoChrom Technologies, where he has held the position of Chief Scientist since its inception. With a significant intellectual contribution, Dr. Liu is credited as the inventor or co-inventor of more than 40 patents and has authored or co-authored over 20 peer-reviewed journal articles and book chapters.
About NanoChrom Technologies:
NanoChrom Technologies is a technology-centric firm specializing in the research, development, and production of chromatography consumables and related applications. Our clientele spans various industries, such as pharmaceuticals, biotechnology, food & beverage, environmental, and chemicals. NanoChrom offers a diverse chromatography consumables range, including ChromCore columns for small molecule separation, BioCore columns for biologics, ChiralCore columns for enantiomer separation, and SelectCore products for sample preparation. Our services encompass technical training, product support, and tailor-made solutions as we collaborate with customers to tackle separation challenges. More information can be found at www.nanochrom.com.